Hypertrophic Cardiomyopathy
Bristol Myers says Camzyos fails Phase 3 study in genetic heart condition
Camzyos, Hypertrophic Cardiomyopathy, Myers, Hypertrophic cardiomyopathy without obstruction, Obstructed, Clinical Trials
Sanofi Acquires Exclusive Rights to Develop and Commercialize Cytokinetics’ Aficamten in Greater China
Sanofi, Cytokinetics, Aficamten, Greater China, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor, Pharmaceutical Deal
Bayer Secures Exclusive Rights to Aficamten in Japan Through Licensing Agreement with Cytokinetics
Bayer, Cytokinetics, Aficamten, Japan, Licensing Agreement, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor